Business Wire

EXCLUSIVE-NETWORKS

9.1.2020 07:02:05 CET | Business Wire | Press release

Share
Global Leadership Hires Drive New Decade of Disruption, Growth and Opportunity at Exclusive Networks

Exclusive Networks today announced the appointments of four new Senior Vice Presidents to complement its existing global leadership team. The appointments of Gerard Allison (SVP, EMEA), Brad Gray (SVP, APAC), Scott Lewis (SVP, Americas) and Barrie Desmond (SVP Marketing & Communications) will provide strategic in-theatre leadership, supporting the company’s continuing success in offering unique local and global value, whilst driving future growth through market leading technologies, innovative services, and disruptive business models, creating value at scale for both vendors and channel partners alike.

“Gerard, Brad, Scott and Barrie are highly experienced operators who will make a valuable contribution to our business in 2020 and beyond,” said Olivier Breittmayer, CEO of Exclusive Networks. “Their arrival coincides with an exciting period of business transformation and innovation as we continue to scale-up and optimise our operational processes for renewed growth in disruptive service offerings, product portfolios and business models.”

Gerard Allison is a highly experienced senior executive with a 30+ year track record of building successful teams in EMEA, working at vendors such as Juniper Networks and, most recently, Gigamon. His extensive expertise and knowledge of the IT and security markets, commercial astuteness, entrepreneurial vision, relationship building and management skills, brings a wealth of experience to the EMEA business.

Brad Gray is a highly experienced senior executive with a 25+ year track record of building successful teams in APAC at vendors such as Juniper Networks, Polycom and, most recently, SAP. Having resided for 20 years in Singapore and for 3 years previously in Indonesia, Brad’s cultural, technological and commercial insights within the region brings a wealth of knowledge and expertise to the APAC business. His appointment comes as the former ‘Asia’ and ‘Pacific’ regions of Exclusive Networks combine as a single ‘APAC’ region.

Scott Lewis is a highly experienced senior executive with a 25+ year track record of regional sales and operations leadership in the Americas, having spent nearly 20 years in the cybersecurity sector working at vendors such as Blue Coat and IBM Internet Security Systems (ISS). Scott joins Exclusive from Fortinet where he spent the last 7 years leading its US Enterprise sales organisation and most recently its US West sales teams.

Barrie Desmond returns to Exclusive following a 12 month sabbatical having previously spent 7 years as Group Marketing Director and most recently as Chief Operations Officer. Barrie has over 30 years experience in marketing, communications and business development, having held senior management roles within channel and vendor organisations, with specialist knowledge and expertise in disruptive technologies and services in cybersecurity and cloud.

The new SVPs bring a wealth of expertise and experience to Exclusive Networks having held senior regional leadership roles at leading global channel and vendor organisations. Each report to Andy Travers, Executive Vice President, Worldwide Sales and Marketing.

“Our global footprint is significant and continually expanding, which emphasises the need for strong leadership at both local and regional levels,” said Andy Travers. “Gerard, Brad, Scott and Barrie are proven business leaders with a strong track record of success and I look forward to working closely with them to take advantage of the growth opportunities within their respective regions.

Their vast experience, knowledge and skills will be a tremendous asset to our business, our partners and our people as we continue to scale-up into a new decade.”

-ends-

About Exclusive Networks
Exclusive Networks is the global specialist VAD for cybersecurity and cloud solutions – the defining and interdependent technologies of the digital era. Its capabilities are backed by best-of-breed vendor portfolios, unparalleled skills and a host of compelling services from pre and post-sales technical support to leasing, training, professional services and global project management. With 50+ offices across five continents and presence in over 100 countries, Exclusive Networks has a unique ‘local sale, global scale’ model, enabling partners to achieve global reach, while delivering the added value of a locally-focused specialist distributor. More at www.exclusive-networks.com .

Link:

ClickThru

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

BeOne Medicines Announces New Phase 3 Survival Data Reinforcing Benefit of ZIIHERA-Containing Regimens in First-Line HER2+ Gastroesophageal Cancer31.8.2026 12:00:00 CEST | Press release

Findings provide further evidence of overall survival benefit of TEVIMBRA plus ZIIHERA and chemotherapy regimen in HER2+ GEAZIIHERA plus chemotherapy demonstrated statistically significant overall survival benefit at second interim analysis of HERIZON-GEA-01 trial BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced positive topline results from the second interim analysis (IA2) of the Phase 3 HERIZON-GEA-01 trial evaluating ZIIHERA® (zanidatamab), in combination with chemotherapy, with and without TEVIMBRA® (tislelizumab), as first-line treatment for HER2+ locally advanced or metastatic gastroesophageal adenocarcinoma (GEA). At IA2, ZIIHERA plus chemotherapy demonstrated a statistically significant and clinically meaningful improvement in overall survival (OS) compared with trastuzumab plus chemotherapy, meeting the remaining primary endpoint analysis of the study. IA2 also provided longer follow-up data for the TEVIMBRA plus ZIIHERA

GigaDevice Strengthens EMEA and Southeast Asia Market Reach Through Strategic Partnership with Rutronik31.8.2026 09:00:00 CEST | Press release

GigaDevice, a leading semiconductor company specializing in Flash memory, 32-bit microcontrollers (MCUs), sensors, and analog products, today announced a new strategic franchise partnership with Rutronik Elektronische Bauelemente GmbH, one of Europe’s leading broadline distributors of electronic components. The agreement covers EMEA and Southeast Asia, including India, and provides customers with broader access to GigaDevice’s comprehensive portfolio of microcontrollers, sensors, and power management solutions. The partnership further strengthens GigaDevice’s distribution network and local market presence across key regions. With its strong presence across Europe and growing coverage in Southeast Asia, Rutronik provides GigaDevice with an established channel supported by extensive market reach, technical expertise, and customer relationships. The collaboration will help expand access to GigaDevice’s embedded solutions across a broad range of applications and industries, including indus

Alnylam Presents New Data at ESC Congress 2026 Reinforcing Strength in RNAi-Powered TTR Silencing Across ATTR-CM Patient Populations and Treatment Settings30.8.2026 14:23:00 CEST | Press release

–Late-Breaking Prespecified Subgroup Analysis of HELIOS-B Demonstrates that Vutrisiran Provided Consistent Clinical Benefit Across All-Cause Mortality and Recurrent Cardiovascular Events in Patients With or Without Tafamidis Use at Baseline ––Additional Post Hoc Analyses Highlight Positive Impact of Vutrisiran in Addressing the Multisystemic Manifestations of ATTR-CM ––Pooled Analysis Across Four Positive Phase 3 Studies of Vutrisiran and Patisiran Shows Consistent Treatment Effect Across Sexes ––New Subgroup Analysis from KARDIA-3 Phase 2 Study of Zilebesiran Highlights Potential to Provide Enhanced Blood Pressure Control – Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, today announced new data at the European Society of Cardiology (ESC) Congress 2026 demonstrating the strength of RNAi-powered silencing for cardiovascular disease. The findings further reinforce the clinical profile of AMVUTTRA® (vutrisiran) across transthyretin amyloidosis (ATTR)

New Auction Record Set as Falcon Sells for AED 1.5 Million at ADIHEX 202629.8.2026 23:54:00 CEST | Press release

Qarmousha Pure Ultra White falcon sells for AED 1.5 million at the Abu Dhabi International Hunting and Equestrian Exhibition 2026 (ADIHEX) falcon auction Under the patronage of His Highness Sheikh Hamdan bin Zayed Al Nahyan, Ruler’s Representative in Al Dhafra Region and Chairman of the Emirates Falconers’ Club, the fifth auction held as part of the 23rd edition of the Abu Dhabi International Hunting and Equestrian Exhibition (ADIHEX) 2026 attracted remarkable turnout, culminating in the sale of a Qarmousha Pure Ultra White falcon for AED 1.5 million (USD 408,000). The sale marks the highest price achieved at any auction during this year’s edition of the exhibition. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260829032621/en/ Qarmousha Pure Ultra White (Photo: AETOSWire) This forms part of the largest auction programme in the exhibition’s history, held under the theme “A Legacy of Pride,” organised by ADNEC Group, a Modon

Takeda Receives U.S. FDA Approval of MIMRYLO™ (rusfertide), Marking a Potential Shift in the Treatment Paradigm for Polycythemia Vera29.8.2026 00:40:00 CEST | Press release

MIMRYLO, a First-in-Class Medicine with a Unique Mechanism of Action, is Approved for the Treatment of Erythrocytosis in Adults with Polycythemia Vera (PV)MIMRYLO Has Been Shown to Maintain Hematocrit Control, the Primary Treatment Goal in PV, as Well as Reduce Phlebotomy Burden and Improve FatigueApproval Supported by Phase 3 VERIFY Results Showing 76.9% of Patients Achieved Clinical Response During Weeks 20-32 Takeda (TSE:4502/NYSE:TAK)announced U.S. Food and Drug Administration (FDA) approval of the New Drug Application (NDA)* for MIMRYLO™ (rusfertide) for the treatment of erythrocytosis in adults with polycythemia vera (PV), a blood cancer. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260824773270/en/ MIMRYLO Logo MIMRYLO is a first-in-class hepcidin mimetic designed to regulate iron distribution in the body and red blood cell overproduction to control hematocrit levels, which is the ratio of red blood cells to the tot

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye